Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAGNODE-3: Diamyd in Recently Diagnosed Type 1 Diabetes
NCT05018585Phase 3Terminated
- Sponsor
- Diamyd Medical
- Start
- May 2022
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Subcutaneous Immunotherapy, Sublingual Immunotherapy
- Countries
- 9
01
Overview
A Phase 3 trial of Diamyd in type 1 diabetes mellitus (T1D), sponsored by Diamyd Medical. Started May 2022; status: terminated.
02
Drugs
Diamyd
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05018585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018585.